Health ❯ Clinical Research ❯ Drug Development ❯ Chimeric Peptides
New Cleveland Clinic data show that treatment discontinuation and low maintenance doses limit semaglutide’s and tirzepatide’s real-world weight-loss benefits, prompting exploration of four-receptor agonists.
